siRNA – Biopharmanalyses

Experimental siRNA therapy SLN360 shows promise for previously untreatable heart disease risk factor

by

Anne-Lise Berthier

Experimental siRNA therapy SLN360 shows promise for previously untreatable heart disease risk factor While there are effective therapies to reduce the risk of heart disease by lowering low-density lipoprotein (LDL), or “bad” cholesterol, and other lipids, to date there are no approved treatments to lower lipoprotein(a), a lesser-known driver of…..

Charcot-Marie Tooth disease: A 100% French RNA-based therapeutic innovation

by

Anne-Lise Berthier

Charcot-Marie Tooth disease: A 100% French RNA-based therapeutic innovation Charcot-Marie Tooth disease is the most common hereditary neurological disease in the world. It affects the peripheral nerves and causes progressive paralysis of the legs and hands. No treatment is currently available to fight this disease, which is due to the…..

Trend Chart on Innovative Bioindustries April 12th

by

Anne-Lise Berthier

Trend Chart on Innovative Bioindustries April 12th FEATURE STORY ● Sirnaomics releases positive interim data from phase II Trial of siRNA candidate studies Sirnaomics, a US-China RNAi therapeutics company, reported on April 9th positive interim results from a Phase II trial of its RNA treatment for non-melanoma skin cancer. STP705…..

NEW: « Gene Therapy Products in Development » (Updated Nov 2019)

by

Anne-Lise Berthier

More than 580 gene therapy products are under development in biotech and pharmaceutical companies for the treatment of more than 240 diseases. More than 200 of these products are now at the clinical stage. After releasing our « Landscape in… Gene Therapy Companies » in September, we now offer you an opportunity…..

NEW: LANDSCAPE IN GENE THERAPY COMPANIES 2019

by

Anne-Lise Berthier

BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report entitled “Landscape… in Gene Therapy Companies”. This report provides you with an in-depth analysis of more than 230 companies involved in this expanding field. (UPDATED SEP 2019) In…..

NEW: LANDSCAPE IN GENE THERAPY COMPANIES

by

Anne-Lise Berthier

Gene Therapy is a rapidly and obviously evolving field that is now definitively recognized as a well-acknowledged major medical and scientific area. BioPharmAnalyses is proud to announce the launch of its new global commercial report "Landscape in Gene Therapy Companies". This is the first such report that provides you with an actually updated information and an accurate international mapping…..

Experimental siRNA therapy SLN360 shows promise for previously untreatable heart disease risk factor

Charcot-Marie Tooth disease: A 100% French RNA-based therapeutic innovation

Trend Chart on Innovative Bioindustries April 12th

NEW: « Gene Therapy Products in Development » (Updated Nov 2019)

NEW: LANDSCAPE IN GENE THERAPY COMPANIES 2019

NEW: LANDSCAPE IN GENE THERAPY COMPANIES

Pages

Archives

BIOPHARMANALYSES

Partenaires